Using flow cytometry, we measured the cell surface expression of LAMP1 (without cell permeabilization) across various organs in a tumor-bearing murine model to evaluate the potential off-target sites for LAMP1-binding radiopharmaceuticals. This evidence concerns the gene LAMP1 and neoplasm.